StockDuty ← Dashboard Nov 06, 2026 04:37 AM ET
SignalEU/UK

Ginkgo reaffirms 2026 cash burn guidance of $125M-$150M while outlining first pharma autonomous lab sale to Novo Nordisk

Ginkgo reaffirmed 2026 cash burn guidance and outlined first pharma autonomous lab sale to Novo Nordisk.

Ginkgo reaffirmed 2026 cash burn guidance and outlined first pharma autonomous lab sale to Novo Nordisk.
Ginkgo reaffirmed 2026 cash burn guidance and outlined first pharma autonomous lab sale to Novo Nordisk. — impact context not separately stored; see What changed.
Sources